185 related articles for article (PubMed ID: 15149825)
1. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
6. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
Messori L; Orioli P; Vullo D; Alessio E; Iengo E
Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
[TBL] [Abstract][Full Text] [Related]
7. Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin.
Ascone I; Messori L; Casini A; Gabbiani C; Balerna A; Dell'Unto F; Castellano AC
Inorg Chem; 2008 Oct; 47(19):8629-34. PubMed ID: 18722420
[TBL] [Abstract][Full Text] [Related]
8. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
[TBL] [Abstract][Full Text] [Related]
9. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
[TBL] [Abstract][Full Text] [Related]
10. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
11. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
[TBL] [Abstract][Full Text] [Related]
12. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
Webb MI; Walsby CJ
Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
[TBL] [Abstract][Full Text] [Related]
14. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Bergamo A; Messori L; Piccioli F; Cocchietto M; Sava G
Invest New Drugs; 2003 Nov; 21(4):401-11. PubMed ID: 14586207
[TBL] [Abstract][Full Text] [Related]
15. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
[TBL] [Abstract][Full Text] [Related]
16. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
[TBL] [Abstract][Full Text] [Related]
17. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
18. Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study.
Levina A; Aitken JB; Gwee YY; Lim ZJ; Liu M; Singharay AM; Wong PF; Lay PA
Chemistry; 2013 Mar; 19(11):3609-19. PubMed ID: 23361836
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
Messori L; Merlino A
Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
[TBL] [Abstract][Full Text] [Related]
20. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz F; Hartmann M; Keppler B; Messori L
J Biol Chem; 1994 Jan; 269(4):2581-8. PubMed ID: 8300587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
